SCA
NYMX

Snowden Capital Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Snowden Capital Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-675
Closed – – 2181
2021
Q4 		$0 Buy
+675
New +$1.08K ﹤0.01% 2190

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Snowden Capital Advisors's NYMX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2022, closing a stake of 675 shares.

Snowden Capital Advisors first reported a position in NYMX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 40 funds tracked by Wall St. Rank hold NYMX as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 675 Nymox Pharmaceutical Corp shares in Q1 2022.
  • Snowden Capital Advisors first reported a position in Nymox Pharmaceutical Corp in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Nymox Pharmaceutical Corp position peaked at $0 in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.